Shots:

• The company has enrolled the first patient in P-I/IIa Study assessing XZ.700 in 48 patients with mild to moderate AD in the Netherlands. This marks the world's 1^st evaluation of a pharmaceutical endolysin for topical use in humans
• The patients will be treated for 14 days with a cream containing XZ.700 at 3 different concentrations vs PBO. The company expects to complete the study and report the results trial by the end of 2021
• XZ.700 is an endolysin targeting S. aureus- including the antibiotic-resistant MRSA- while preserving Staphylococcus epidermidis- that is beneficial on the skin and helps in healing wounds. XZ.700 targets multiple indications including AD- diabetic wound infections- and cutaneous T-cell lymphoma

­ Ref: PRNewswire | Image: Micreos